[1] |
WEI Hongtao, SHEN Su, LI Dandan, LIAO Yin.
Pareto chart analysis of 705 problematic prescriptions in neurology
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 900-903.
|
[2] |
LIU Min, PEI Xiaojing, WANG Haixue.
Problems with and suggestions about expedited reporting of suspected unexpected serious adverse reactions during clinical trials of drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 176-179.
|
[3] |
LI Yiyun, LIAO Caiyun, PAN Jing, WEN Baoshu.
A Comparative Study of Chinese and American Orange Books Based on the 5W Model
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 806-809.
|
[4] |
HUANG Zhengkai, ZHANG Bing, LIN Zhijian, ZHANG Xiaomeng, ZHANG Dan, YIN Yuling.
The Analysis and Thought of Safety Problem and Rational Application of Anthraquinones-Containing Traditional Chinese Medicine
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 532-536.
|
[5] |
LI Xinxu, TANG Zhimin, ZHOU Jun, WANG Jun.
Limitations of the Safety Assessment in Premarketing Clinical Trials of Drugs and Suggestions for Improvement
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 465-470.
|
[6] |
SANG Yuan, WU Shifu, LU Changfei, XIE Yanjun, CUI Xiaokang, XU Lili, LIU Wenwen, HUO Yanfei.
Problems and Thoughts on Reporting and Monitoring of Adverse Drug Reactions in Drug Manufacturers
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 215-218.
|
[7] |
HONG Wei, WANG Feng.
Current Construction of Monitoring and Evaluation System of Adverse Drug Reactions in Anhui Province
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 722-726.
|
[8] |
GONG Li-xiong, WANG Chang-zhi, CHEN Chao, YANG Yue, CHEN Jian-gang, GUO Hui, MA Xue-jiao, LIU Chao.
Study on Risk Classification and Management of ADR Monitoring Varieties in Pharmaceutical Enterprises in Henan Province
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(3): 169-175.
|
[9] |
FAN Ying-ying, QI Ying-ying, MU Xing-jia, WANG Chen-hui, JIANG Qing-dan, QIAO Ming-juan.
Suggestions on Improvement of Administrative Regulations on Narcotic Drugs and Psychotropic Drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(1): 28-31.
|
[10] |
XU Gan.
Analysis on Validity Periods of Leftover Medicines in Medicine Instructions in China
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(2): 95-98.
|
[11] |
FAN Yan, XIA Dong-sheng.
Problems and Countermeasures of Labeling Contents of Using in the Elderly in Medicine Instructions in China
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(6): 341-343.
|
[12] |
ZHANG Zhao-hui.
Risks and Suggestions of Appliance in Orthodontics
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(6): 366-367.
|
[13] |
XIA Dong-sheng.
Recommendations on Risk Control and Analysis of the Problems Existing on Labeling Contents of Medicines Used for Pregnant and Lactating Women in Package Inserts in China
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(4): 211-218.
|
[14] |
ZHENG Ming-jie, XIA Dong-sheng.
Problem Analysis and Suggestion on Application Materials of OTC Switch
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 618-622.
|
[15] |
WEI Shu-min, ZHEN Zhi-qin, LI Ke-nan.
Role of Pharmaceutical Enterprise in Periodic Safety Update Report
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(9): 547-549.
|